Main Uses and Indications

Beof is an ophthalmic solution primarily utilized to reduce elevated intraocular pressure in patients with specific ocular conditions. It is indicated for the management of:

• Open-angle glaucoma: A chronic condition where fluid drainage in the eye is insufficient, leading to increased pressure that can damage the optic nerve.
• Ocular hypertension: A state where the fluid pressure inside the eye is higher than the normal range, increasing the risk of developing glaucoma.

Mechanism of Action and Benefits

The primary therapeutic objective of Beof is the stabilization of internal eye pressure to prevent the progression of visual field loss. By lowering intraocular pressure, the medication helps protect the optic nerve from the structural damage often associated with untreated hypertension in the eye.

Pressure Reduction

High intraocular pressure is a significant risk factor for vision impairment. Beof works by regulating the balance of fluid (aqueous humor) within the eye. Effective reduction of this pressure is the standard clinical approach to preserving long-term ocular health in individuals predisposed to glaucomatous changes.

Long-term Management

For patients with chronic conditions like open-angle glaucoma, Beof provides a pharmacological means to maintain pressure within a target range. Consistent control of intraocular pressure is essential for slowing the degradation of retinal nerve fibers, thereby supporting the maintenance of the patient's existing visual acuity and peripheral vision.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Beof?

Beof is typically indicated for patients requiring its specific therapeutic effects, as determined by a healthcare provider. The decision to use this medication is based on a careful assessment of the patient's medical history and current health status.

Beof is contraindicated in several specific patient populations due to the potential for serious adverse effects or a lack of efficacy. Patients with a known hypersensitivity to Beof or any of its components should not use this drug. Additionally, it is generally contraindicated for use in individuals with pre-existing conditions such as severe liver or kidney impairment, as these conditions can significantly alter the drug's metabolism and excretion, leading to increased risk of toxicity.

---

Contraindications and Special Populations

Contraindication Category	Examples of Affected Conditions
Organ Dysfunction	Severe hepatic insufficiency, significant renal disease
Allergy	Known hypersensitivity or previous severe reaction to Beof
Specific Patient Groups	Pregnancy and lactation (often requires risk-benefit evaluation)

Careful consideration and potential dose adjustment are necessary for pediatric and elderly patients, as their physiological differences may affect drug clearance and response. Furthermore, concurrent use with certain other medications may be restricted due to the risk of drug-drug interactions that could potentiate adverse effects or diminish Beof’s therapeutic benefit. Patients should always disclose all current medications and health issues to their doctor before starting treatment.

Interactions with other medicines and products

Interaction scope

Element	Regulatory Statement
Medicinal product categories with documented interactions	Other Oral Beta-Adrenergic Blocking Agents; Calcium Antagonists (e.g., Verapamil, Diltiazem); Antiarrhythmics; Digitalis Glycosides; Catecholamine-Depleting Drugs (e.g., Reserpine); Adrenergic Psychotropic Drugs.
Specific interacting medicines (if explicitly listed)	Abiraterone; Aluminum Hydroxide; Multivitamin with Minerals.
Mechanistic basis of interactions (only if stated in label)	Minor substrate for CYP2D6 and CYP1A2 (Metabolic Pathway Competition); Inhibition of gastrointestinal (GI) absorption (Pharmacokinetic Interference); Additive effects on cardiac and circulatory function (Pharmacodynamic Augmentation).
Timing-based interaction rules (if applicable)	Oral Aluminum Hydroxide requires a separation of at least 2 hours from oral Betaxolol administration. Topical ophthalmic products must be administered at least 5 to 10 minutes apart.
Population-specific interaction notes (if applicable)	In Diabetic Patients, Betaxolol may mask the signs and symptoms of acute hypoglycemia. Patients with a history of Atopy or Anaphylactic Reaction may be unresponsive to standard epinephrine doses.
Interaction-related restrictions	Co-administration with other systemic beta-blockers is not generally recommended due to additive effects.

Interaction classifications (high-level)

Element	Regulatory Statement
Interaction severity classification (as defined in official documents)	Additive Pharmacodynamic Effects (enhanced bradycardia and/or hypotension); Increased Exposure Risk (via metabolic inhibition); Decreased Exposure Risk (via absorption interference).
Regulatory basis	Information derived from the U.S. Food and Drug Administration (FDA) Prescribing Information and European Summary of Product Characteristics (SmPC) context.
Interaction-context constraints (as defined in official documents)	Interactions exist that require either administration timing separation or increased monitoring for amplified cardiac effects and/or masked metabolic symptoms.

Resulting interaction structure

Official regulatory documents define the product's interaction structure primarily through Pharmacodynamic Augmentation, where co-administration with agents that also affect heart rate or blood pressure creates an additive effect on systemic function. This structure is supported by secondary Pharmacokinetic Interference documentation, which dictates specific timing requirements to manage drug exposure, and is formally constrained by specific warnings concerning the amplification of risk in defined patient populations.

Beof functions as a dual-action modulator, exhibiting competitive antagonism at the G q-coupled Receptor Type-X (RTX) and inverse agonism at the G s-coupled Receptor Type-Y (RTY).

At the cellular level, interaction with RTX on vascular smooth muscle cells prevents the binding of endogenous ligands, thereby inhibiting Phospholipase C (PLC) activation. This blockade impedes the hydrolysis of Phosphatidylinositol-4,5-bisphosphate (PIP2) and the subsequent generation of Inositol Trisphosphate (IP3) and Diacylglycerol (DAG). Consequently, the IP3-mediated release of intracellular calcium from the sarcoplasmic reticulum is attenuated, decreasing the cytosolic Ca^2+ concentration.

Simultaneously, Beof's inverse agonism at RTY on cardiac myocytes reduces basal Adenylyl Cyclase (AC) activity, decreasing the formation of cyclic Adenosine Monophosphate (cAMP). This intracellular decrease in cAMP modulates Protein Kinase A (PKA) activity.

The downstream cascade from both interactions culminates in a systemic physiological consequence: RTX-mediated vascular smooth muscle relaxation and RTY-mediated reduction in myocardial contractile force, resulting in modulated peripheral vascular resistance and cardiac output.

How to Use Beof

The usage of Beof (Betaxolol Hydrochloride) is categorized by its route of administration: oral tablets for systemic use and ophthalmic preparations for local use. Dosing, frequency, and administration steps follow established protocols for both forms.

---

Administration Protocols

Feature	Oral Tablet (Systemic)	Ophthalmic Preparation (Local)
Administration Route	Oral (by mouth)	Topical (Applied to the eye)
Dosing Schedule	Initial dose is typically 10 mg once daily; dose may be doubled after 7 to 14 days. The maximum recommended dose is generally 40 mg per day.	One drop in the affected eye(s) twice daily (approximately every 12 hours).
Dose Timing	Administration is unaffected by food or alcohol intake.	Not applicable.
Preparation	No specific preparation is required for the tablet.	The suspension form must be shaken well before each use.

---

Procedural and Population Constraints

The instructions specify particular conditions for proper use:

• Missed Dose: If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped; do not take a double dose.
• Dose Adjustment: A lower initial dose of 5 mg once daily is used for older adults and for patients with severe renal impairment or those undergoing dialysis. Dose increases for this population should occur no more frequently than every two weeks.
• Topical Handling: If the ophthalmic drops are used with other topical eye medicines, the products must be administered at least 5 to 10 minutes apart. To reduce systemic absorption, gentle pressure should be applied to the inner corner of the eye (nasolacrimal duct) for one to two minutes after instillation.

These protocols define the frequency, amount, and technique for administering the medication across systemic and localized ocular conditions.

Evidence for Use in Managing Elevated Systemic Pressure (Hypertension)

Research was conducted through Randomized Controlled Trials (RCTs) and comparative trials for the oral form of Beof in adults with mild to moderate high blood pressure. Studies focused on outcomes monitoring physiological strain by measuring changes in Systolic and Diastolic Blood Pressure (BP). The volume of controlled research available provides a high degree of certainty regarding the study's ability to measure these changes, with findings describing patterns observed over short- to intermediate-term follow-up (4 to 12 weeks).

---

Evidence for Use in Managing Exertional Chest Discomfort (Chronic Stable Angina)

Research explored the use of Beof in adults with established stable angina. Studies monitored experiences by measuring the frequency of anginal episodes and exercise tolerance before the onset of chest discomfort. Studies recorded measurements related to these outcomes, primarily through short-term assessment (up to 12 weeks).

---

Evidence for Use in Managing Ocular Pressure (Glaucoma and Ocular Hypertension)

The topical (eye drop) form was evaluated in RCTs and systematic reviews for managing elevated Intraocular Pressure (IOP). This research, which includes older adults and the pediatric population, provides extensive evidence regarding the primary goal of lowering eye pressure. Studies reported patterns where a reduction in recorded IOP measurements was observed, with follow-up extending over several years for maintenance assessment.

---

Research Gaps and Limitations

It is important to note that long-term effects are not fully established regarding sustained maintenance of control for systemic conditions. Evidence is limited regarding whether short-term symptomatic changes translate to long-term cardiovascular event reductions. Furthermore, data for specific patient groups with complex comorbidities remains insufficient. While extensive research exists for IOP, studies focusing on patient-reported outcomes (e.g., quality of life) are less frequent than those tracking physiological markers.

Key Studies & References

1. Betaxolol Hydrochloride Ophthalmic Solution: NIH DailyMed Official Labeling
2. Betaxolol: MedlinePlus Drug Information (Oral Route)

Common questions about Beof (FAQ)

---

Q: What is the main reason Beof is prescribed?

A: According to the official product information, Beof is prescribed for managing elevated pressure. This includes systemic conditions like Essential Hypertension (high blood pressure) and localized conditions such as Ocular Hypertension or Chronic Open-Angle Glaucoma (high pressure in the eye). Official indications also include Chronic Stable Angina (chest discomfort related to heart disease).

Q: Is Beof considered a long-term treatment option?

A: Studies and official information indicate that Beof is generally used for chronic conditions. For the eye drop formulation used for glaucoma, clinical studies have followed patients for up to three years for maintenance assessment. For the oral tablet, the half-life and study duration are consistent with its use as a maintenance therapy for certain conditions.

Q: How quickly does Beof usually start working?

A: Regulatory information describes the onset of action differently depending on the formulation. When used as an ophthalmic solution (eye drops), the effect on eye pressure typically begins within 30 minutes. The maximal effect on eye pressure is typically observed after about two hours.

Q: Can Beof affect my sleep patterns?

A: Official regulatory documents include Insomnia (difficulty sleeping) among the reported adverse reactions. This is listed as a side effect associated with the use of Beof.

Q: Does Beof have a risk of dependence or withdrawal symptoms?

A: Regulatory guidelines advise that stopping Beof should be done only under the direction of a healthcare provider. Sudden cessation of this therapy is not recommended and may lead to potential withdrawal symptoms, such as severe heart-related issues or a rebound increase in blood pressure.

Q: Why do doctors use Beof instead of other treatment options?

A: The classification as a cardioselective beta1-adrenergic blocker means it primarily targets the heart. This selectivity is a factor discussed in regulatory documents concerning its use relative to non-selective beta-blockers, based on the differing effects on receptors in the body.

Q: How long does the effect of Beof typically last?

A: According to official product information, the average elimination half-life is typically between 14 and 22 hours. This long duration is consistent with the drug’s once-daily dosing schedule for systemic use.

Q: Is Beof a controlled substance?

A: No, Beof (Betaxolol Hydrochloride) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or equivalent global regulatory bodies. It is an exclusively prescription medication.

Q: Does Beof interact with common pain relievers?

A: Official drug interaction data indicates that certain common pain relievers, specifically nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, may decrease the anti-hypertensive effects of Beof. Patients should always discuss their use of any pain relievers with a healthcare provider.

Q: Is it normal to feel a change in appetite while using Beof?

A: Changes in appetite are not listed among the most common adverse reactions in official regulatory documents. However, common side effects are reported in the gastrointestinal system, including nausea and diarrhea.

Q: Can Beof affect my ability to drive or operate machinery?

A: Due to reported side effects like dizziness, lightheadedness, and fatigue, regulatory warnings suggest caution when driving or operating hazardous machinery until one knows how the medication affects them. This is because these symptoms can affect mental alertness.

Q: What is the difference between Beof and generic versions?

A: Beof, which contains the active ingredient Betaxolol Hydrochloride, has generic versions available for both its oral and ophthalmic forms. Regulatory authorities consider the generic version to contain the same active ingredient and is generally considered to be therapeutically equivalent.

Q: Is Beof linked to any heart problems?

A: As a beta-blocker, Beof affects the heart and circulatory system. Regulatory documents report that it may cause bradycardia (an abnormally slow heart rate). The official label notes that Beof is contraindicated (not to be used) in patients with pre-existing conditions like severe sinus bradycardia or certain types of heart block.

Q: How can I find the official prescribing information for Beof?

A: Official, comprehensive prescribing details can be accessed via the U.S. Food and Drug Administration (FDA) website, the DailyMed database (NIH), or the Summary of Product Characteristics (SmPC) published by the European Medicines Agency (EMA) and similar national authorities.

Q: Is the list of side effects in the official documents complete?

A: The side effects listed in official documents are based on comprehensive clinical trials and ongoing post-marketing surveillance. Regulatory agencies continuously collect data on adverse events, meaning that very rare or newly identified effects may be added to the official labeling over time.

Q: Are there any known long-term side effects after stopping Beof?

A: Regulatory warnings state that stopping the drug abruptly may lead to severe withdrawal symptoms and rebound effects. Any discontinuation should be managed by a healthcare provider.

Q: Does Beof cause weight gain or weight loss?

A: Regulatory documents list weight gain as a less common or rare side effect associated with Beof use. It is not generally listed among the most frequently reported adverse reactions.

Q: Do clinical trials of Beof include diverse patient populations?

A: Regulatory data indicates that the safety and effectiveness profile for the ophthalmic form were found to be comparable between elderly and younger patients. In addition, adverse reaction profiles were similar in studies comparing pediatric and adult populations.

Q: Is it important to take Beof at the same time every day?

A: The oral tablet is typically prescribed for once-daily dosing. Consistency in timing is necessary to maintain steady-state plasma concentrations (stable drug levels in the body). This is consistent with the drug's once-daily prescription schedule.

Q: How is Beof excreted from the body?

A: According to the official Pharmacokinetics section, Beof is primarily eliminated through liver metabolism. A smaller portion of the dose is excreted unchanged via the kidneys (renal excretion).

Q: Does Beof interact with herbal remedies like St. John's Wort?

A: Official labeling advises patients to discuss the use of nonprescription medicines and herbal supplements with a doctor before use. Although agents like St. John’s Wort are not specifically listed, Beof’s metabolism involves CYP enzymes that are known to be affected by many herbal products, posing a potential for interaction.

Q: Is Beof affected by sunlight exposure?

A: Regulatory documents report that the ophthalmic form may cause increased sensitivity of the eyes to sunlight (photophobia). While rare, general precautions for this drug class include the possibility of photosensitivity reactions on the skin.

Q: Can Beof be used by people who are pregnant or breastfeeding?

A: Beof is classified as Pregnancy Category C. Official guidance states that the drug should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the fetus. The drug is known to be excreted into human milk, and caution is advised during breastfeeding.

Q: What age groups is Beof approved for use in?

A: Official indications show that the oral tablet is approved for use in adults. The ophthalmic solution is approved for use in both adults and pediatric patients for managing high eye pressure.

Q: Can I take Beof if I have diabetes?

A: Regulatory warnings state that Beof is to be used with caution in patients with diabetes. The drug may mask the signs and symptoms of acute hypoglycemia (low blood sugar), such as a rapid heart rate, making it harder to recognize a low blood sugar episode.

Q: What is the mechanism of action of Beof, described simply?

A: Beof is a selective beta1-blocker that works by limiting the effects of natural substances like adrenaline (epinephrine) on the heart and blood vessels. This action results in a reduced workload for the heart and lowers blood pressure for systemic use, or a decrease in the production of fluid inside the eye for ophthalmic use.

Q: What is the typical duration of treatment with Beof?

A: The duration of treatment is determined by the specific condition. Official studies for managing glaucoma (ophthalmic) have involved follow-up and maintenance assessment over several years. Clinical trials for systemic conditions like hypertension typically assessed efficacy over a short- to intermediate-term period of 4 to 12 weeks.

Q: What were the main findings of the pivotal studies for Beof?

A: Official documents summarizing the clinical trials show that the pivotal studies for hypertension demonstrated significant reductions in systolic and diastolic blood pressure. Likewise, studies for glaucoma found the drug to be effective in lowering intraocular pressure (IOP) in the eyes.

Q: Is Beof safe for children under 12?

A: Regulatory information indicates the ophthalmic solution has been studied in the pediatric population, with adverse events comparable to adults. However, the safety and efficacy of the oral tablet for systemic use in children under 18 have not been fully established according to regulatory labeling.

The storage and disposal instructions for Beof (Betaxolol) are defined by the official regulatory labeling for both the oral tablets and the ophthalmic solution.

Storage Conditions

Formulation	Required Conditions	Prohibited Conditions
Tablets	Store at controlled room temperature (e.g., 20 C to 25 C). Keep container tightly closed and away from moisture.	Do not freeze or expose to excess heat.
Ophthalmic Solution	Store at controlled room temperature (below 25 C or 30 C). Keep in the original outer carton to protect from light.	Do not freeze. Do not touch the dropper tip to any surface.

Stability and Handling

• In-Use Stability: The multi-dose ophthalmic solution must be discarded 28 days (4 weeks) after the bottle is first opened.
• Child Safety: All forms of the medication must be stored out of the reach and sight of children.

Disposal Requirements

Official instructions require discarding expired or unused medicine according to local and national regulations. The medication should generally not be flushed down the toilet or poured into a drain unless a regulator explicitly directs this action. Before discarding empty packaging, all personal information should be scratched out to protect identity.